Coronado Biosciences, Inc. has formed a wholly owned subsidiary called, Journey Medical Corporation (JMC) to acquire and license dermatology products.

Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid responsive dermatoses, pigmentation and antifungals for promotion to dermatologists and pediatricians.

Coronado's Chairman, President and CEO, Dr. Lindsay A. Rosenwald said,"Forming a specialized pharmaceutical company that focuses on dermatology will enable Coronado to diversify its business. Claude has a history of success in commercializing brands at top companies in this space, and we feel confident about his ability to bring this record of success to JMC."

"Our goal is to aggregate a strong line of dermatologics that benefit patients. We believe that combining the support of Coronado and our expertise in dermatology will accomplish this quickly," Mr. Maraoui said.

Go to: http://www.coronadobiosciences.com/ for more information.